Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors

Rutgers University25 enrolled

Overview

There is a high incidence among the first degree relatives of the carcinoid patients, indicating the involvement of genetic components in its initiation and pathogenesis.

This proposed pilot study will conduct detailed interviews into the medical, environmental, and family histories and to collect blood specimen to obtain DNA. The Blood specimen and DNA will be processed by the Rutgers University Cell and DNA Repository (RUCDR) to rule out Familial Multiple Endocrine Neoplasia (MEN 1), and succinate dehydrogenase complex, subunit D (SDHD), gene inactivation thought to be associated with different types of carcinoid cancer.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Carcinoid Neuroendocrine Cancer

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Over the age of 18 years 2. More than one ,member of a family with a history of biopsy confirmed carcinoid tumor 3. English speaking 4. Mentally and emotionally capable of answering questions 5. Willing and available for study participation 6. At least one other family member with carcinoid tumor Exclusion Criteria: 1. If you are under the age of 18 years, 2. If you are unable to understand or unable to provide informed consent, 3. If you have a psychological condition (i.e. depression, anxiety disorder, substance abuse, etc.) which might cause you significant problems in dealing with test results.

Locations (1)

Busch Campus of Rutgers University, Human Genetics Institute

Piscataway, New Jersey, United States

RECRUITING

Outcomes

Primary Outcomes

Mutations in MEN1 and SDHD genes

Time frame: 1 year

Central Contacts

Nancy Gardner, PhD

CONTACT

813-731-0894 gardnern@rutgers.edu

Changshun Shao, PhD

CONTACT

Shao@Biology.Rutgers.Edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.